Payment overview · 2025
General Payments
$516.28
23 reported records · 10 companies
Healthcare provider profile · identity verified
Marcy Jackovic
Allopathic & Osteopathic Physicians|Internal Medicine · PORT CHARLOTTE, FL · NPI 1699744888
Verified facts
What the public records show
CMS Open Payments records show Marcy Jackovic received $516.28 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $201.96 | 39.1% | 9 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $84.94 | 16.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.26 | 12.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.00 | 8.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.91 | 7.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.67 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.60 | 4.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.13 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.05 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.76 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $516.28 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $175.19 | 8 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $84.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.71 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.92 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.92 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.00 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.91 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.91 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 356 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 105 |
| Losartan Potassium | Losartan Potassium | 262 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 191 | 68 |
| Lisinopril | Lisinopril | 182 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 62 |
| Omeprazole | Omeprazole | 137 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 52 |
| Gabapentin | Gabapentin | 122 | 39 |
| Metformin Hcl | Metformin Hcl | 118 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 40 |
| Simvastatin | Simvastatin | 93 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 26 |
| Trazodone Hcl | Trazodone Hcl | 89 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 34 |
| Furosemide | Furosemide | 82 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 42 |
| Montelukast Sodium | Montelukast Sodium | 79 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 36 |
| Famotidine | Famotidine | 77 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 28 |
| Alprazolam | Alprazolam | 60 | 18 |
| Atenolol | Atenolol | 58 | 18 |
| Ozempic | Semaglutide | 58 | 12 |
| Tramadol Hcl | Tramadol Hcl | 58 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 23 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Potassium Chloride | Potassium Chloride | 55 | 17 |
| Sertraline Hcl | Sertraline Hcl | 54 | 19 |
| Celecoxib | Celecoxib | 53 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 14 |
| Eliquis | Apixaban | 48 | 13 |
| Meloxicam | Meloxicam | 48 | 16 |
| Lorazepam | Lorazepam | 47 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Carvedilol | Carvedilol | 45 | 14 |
| Methylprednisolone | Methylprednisolone | 44 | 37 |
| Alendronate Sodium | Alendronate Sodium | 39 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 34 |
| Prednisone | Prednisone | 38 | 26 |
| Synthroid | Levothyroxine Sodium | 38 | 14 |
| Azithromycin | Azithromycin | 37 | 31 |
| Metformin Hcl Er | Metformin Hcl | 37 | 14 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 13 |
| Bupropion Xl | Bupropion Hcl | 34 | 13 |
| Ketoconazole | Ketoconazole | 34 | 25 |
| Cephalexin | Cephalexin | 33 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 23 |
| Amoxicillin | Amoxicillin | 31 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | 13 |
| Clonazepam | Clonazepam | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | 13 |
| Ondansetron Odt | Ondansetron | 26 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 15 |
| Baclofen | Baclofen | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | 12 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Nystatin | Nystatin | 21 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | 11 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Fluconazole | Fluconazole | 12 | 11 |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $516.28 · 23 records | ABBVIE INC. | Da Vinci Surgical System, Dexcom G6 Transmitter, GEMTESA, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, Veozah, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error